Mike Mehan leads the Multiomics Bioinformatics group at Illumina, driving innovations in epigenomics, transcriptomics, and proteomics. Illumina is a global leader in next-generation sequencing and enables researchers and clinicians to gain deeper insights from genomics data. Mike contributes to Illumina’s mission of transforming human health by working with his team to develop algorithms and software for Illumina’s portfolio of multiomics products. This new multiomics direction in sequencing combines diverse biological data to deliver a complete view of complex systems, unlocking new potential in disease diagnosis, customized therapies, and personalized medicine.